Real-world outcomes of talimogene laherparepvec as salvage therapy for advanced melanoma

Background Talimogene laherparepvec (T-VEC) is an oncolytic herpes simplex virus therapy approved for treatment of unresectable and metastatic melanoma. However, real-world use often occurs in heavily pretreated patients, where evidence of effectiveness remains limited. This study evaluates treatmen...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Shailender Bhatia, Paul T Nghiem, George Ansstas, Song Y Park, Coley Doolittle-Amieva, Evan T Hall, Melissa M Yamada, Smitha Chandrasekhar, Ted A Gooley, Rita E Chen, David Y Chen
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	BMJ Publishing Group 2025-12-01
Edice:	Journal for ImmunoTherapy of Cancer
On-line přístup:	https://jitc.bmj.com/content/13/12/e013564.full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!